Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aridis Pharmaceuticals Inc | ARDS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.289 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.289 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.16 - 0.5395 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.289 | USD |
Aridis Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 12.93M | 44.57M | - | 3.09M | -30.37M | -0.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aridis Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/13/2024 | 19:02 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/16/2024 | 05:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/15/2023 | 15:15 | GlobeNewswire Inc. | Aridis Pharmaceuticals Announces Adjournment of Annual.. |
| 11/03/2023 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/03/2023 | 15:15 | GlobeNewswire Inc. | Aridis Pharmaceuticals Announces Third Quarter 2023.. |
| 11/03/2023 | 05:15 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 9/13/2023 | 20:47 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 9/07/2023 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/25/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/04/2023 | 15:05 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 8/03/2023 | 15:15 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 8/02/2023 | 07:17 | GlobeNewswire Inc. | Aridis Pharmaceuticals Announces $2 Million Offering |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARDS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.228 | 0.5395 | 0.16 | 0.3588879 | 5,048,035 | 0.061 | 26.75% |
| 3 Years | 5.82 | 7.72 | 0.15 | 1.08 | 1,034,595 | -5.53 | -95.03% |
| 5 Years | 10.07 | 12.40 | 0.15 | 1.14 | 548,122 | -9.78 | -97.13% |
Aridis Pharmaceuticals Description
| Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. |
